Eran Broshy Net Worth

The estimated Net Worth of Eran Broshy is at least $1.29 Milione dollars as of 21 May 2024. Mr. Broshy owns over 8,663 units of Theravance Biopharma Inc stock worth over $186,486 and over the last 16 years he sold TBPH stock worth over $754,310. In addition, he makes $353,379 as Independent Director at Theravance Biopharma Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mr. Broshy TBPH stock SEC Form 4 insiders trading

Eran has made over 6 trades of the Theravance Biopharma Inc stock since 2016, according to the Form 4 filled with the SEC. Most recently he exercised 8,663 units of TBPH stock worth $70,170 on 21 May 2024.

The largest trade he's ever made was exercising 9,360 units of Theravance Biopharma Inc stock on 23 May 2023 worth over $75,816. On average, Eran trades about 1,092 units every 91 days since 2009. As of 21 May 2024 he still owns at least 23,023 units of Theravance Biopharma Inc stock.

You can see the complete history of Mr. Broshy stock trades at the bottom of the page.

Eran Broshy biography

Eran Broshy serves as Independent Director of the Company. Mr. Broshy has been an operating executive with Tailwind Capital, a New York based private equity firm, supporting their healthcare investment efforts since September 2015. From March 2013 until August 2015, he worked with Linden Capital Partners and Court Square Capital, both private equity firms, as operating partner and executive advisor, respectively, and from June 2009 until December 2012 he worked with Providence Equity Partners as a senior advisor supporting the private equity firm's healthcare information investment efforts. Mr. Broshy previously served for over a decade as the chief executive officer (until 2008) and chairman of the board of directors (until 2010) of inVentiv Health, Inc., a privately held company (and until August 2010 a Nasdaq listed company) that delivers a broad range of clinical and commercialization services to pharmaceutical and life sciences companies globally. Prior to joining inVentiv, Mr. Broshy was a management consultant with The Boston Consulting Group (BCG) for 14 years, including as the partner responsible for BCG's healthcare practice across the Americas. He also served as president and chief executive officer of Coelacanth Corporation, a privately held biotechnology company. He currently serves on the board of directors of Magellan Health, Inc., a public specialty health care management company, and within the previous five years Mr. Broshy has also served on the board of directors of inVentiv Health, Inc. He also serves as chairman of the board of ERT and of DermaRite, both privately-held healthcare companies, as a member of the Corporation of the Massachusetts Institute of Technology ("MIT"), as well as on the board of directors of the American Jewish Committee NY and the Israel Venture Network. Mr. Broshy holds an M.B.A. from Harvard University, an M.S. in civil engineering from Stanford University, and a B.S. in civil engineering from the Massachusetts Institute of Technology.

What is the salary of Eran Broshy?

As the Independent Director of Theravance Biopharma Inc, the total compensation of Eran Broshy at Theravance Biopharma Inc is $353,379. There are 16 executives at Theravance Biopharma Inc getting paid more, with Rick Winningham having the highest compensation of $5,932,410.

How old is Eran Broshy?

Eran Broshy is 61, he's been the Independent Director of Theravance Biopharma Inc since 2014. There are 9 older and 17 younger executives at Theravance Biopharma Inc. The oldest executive at Theravance Biopharma Inc is Burton Malkiel, 87, who is the Independent Director.

What's Eran Broshy's mailing address?

Eran's mailing address filed with the SEC is C/O CERTARA, INC., 100 OVERLOOK CENTER, SUITE 101, PRINCETON, NJ, 08540.

Insiders trading at Theravance Biopharma Inc

Over the last 11 years, insiders at Theravance Biopharma Inc have traded over $11,619,559 worth of Theravance Biopharma Inc stock and bought 4,008,513 units worth $29,986,832,769,275 . The most active insiders traders include Plc Gsk, Inc. Innoviva, e Eli Samaha. On average, Theravance Biopharma Inc executives and independent directors trade stock every 57 days with the average trade being worth of $448,635. The most recent stock trade was executed by Eli Samaha on 7 August 2024, trading 999,800 units of TBPH stock currently worth $7,798,440.

What does Theravance Biopharma Inc do?

theravance biopharma is a biopharmaceutical company with one approved product, vibativ® (telavancin), that was discovered and developed internally, a pipeline of internally discovered product candidates and strategic collaborations with pharmaceutical companies.

Complete history of Mr. Broshy stock trades at Magellan Health Inc, Theravance Biopharma Inc e Certara

Theravance Biopharma Inc executives and stock owners

Theravance Biopharma Inc executives and other stock owners filed with the SEC include:

• Rick Winningham,
  Chairman of the Board, Chief Executive Officer
• Andrew Hindman,
  Chief Financial Officer, Senior Vice President
• Bradford Shafer,
  Executive Vice President, General Counsel, Secretary
• Brett Haumann,
  Senior Vice President, Clinical Development and Chief Medical Officer
• Frank Pasqualone,
  Senior Vice President and Chief Commercial Operations Officer
• Philip Worboys,
  Senior Vice President - Research and Translational Science
• Rick E. Winningham M.B.A.,
  Chairman & CEO
• Andrew Asa Hindman,
  Sr. VP & CFO
• Bradford J. Shafer,
  Exec. VP, Gen. Counsel & Sec.
• Andrew Asa Hindman M.B.A,
  Sr. VP & CFO
• Rhonda F. Farnum,
  Chief Bus. Officer and Sr. VP of Commercial & Medical Affairs
• William Young,
  Lead Independent Director
• Burton Malkiel,
  Independent Director
• Donal O'Connor,
  Independent Director
• Dean Mitchell,
  Independent Director
• Susan Molineaux,
  Independent Director
• Eran Broshy,
  Independent Director
• Laurie Alsup,
  Independent Director
• George Whitesides,
  Independent Director
• Robert Gunderson,
  Director
• Deepika Pakianathan,
  Independent Director
• Vijay Sabesan,
  Senior Vice President - Technical Operations
• Kenneth Pitzer,
  Senior Vice President - Product Strategy and Commercial Planning
• Ann Brady,
  President - Theravance Biopharma Ireland Limited
• Dr. Ann B. Brady Ph.D.,
  Pres of Theravance Biopharma Ireland Limited
• Dr. Richard A. Graham Ph.D.,
  Sr. VP of Devel.
• Daniel Long,
  Head of Medicinal Chemistry
• Dr. Kenneth R. Pitzer,
  Sr. VP of Product Strategy & Commercial Planning
• Dr. Phillip D. Worboys,
  Sr. VP of Research & Translational Science
• Dennis O. Driver,
  Sr. VP of HR, Organizational and Leadership Devel.
• Gail B. Cohen,
  VP of Corp. Communications & Investor Relations
• Jeremy T Grant,
  
• Renee D Gala,
  VP-Finance
• Peter S Ringrose,
  Director
• Junning Lee,
  Sr. VP, Technical Operations
• Sharathchandra S Hegde,
  SVP, Research
• Henrietta Fore,
  Director
• Shehnaaz Suliman,
  SVP, Corp Dev & Strategy
• Jeffrey David Jonker,
  Senior VP, Corp. & Bus. Dev.
• Michael G Atieh,
  Director
• Leonard M Blum,
  Sr VP, Chief Comm. Officer
• Inc. Innoviva,,
  10% owner
• Mathai Mammen,
  SVP, Research & Early Clin Dev
• Rhonda Farnum,
  SVP, COMM & MEDICAL AFFAIRS
• Richard A Graham,
  SVP, RESEARCH & DEVELOPMENT
• Plc Gsk,
  
• Aziz Sawaf,
  SVP & CHIEF FINANCIAL OFFICER
• Brett A. Grimaud,
  SVP, GEN COUNSEL AND SECRETARY
• Susannah Gray,
  
• Aine Miller,
  SVP, DEV & HEAD OF IRE OFFICE
• Eli Samaha,
  10% owner